By Matthew Pillar, Editor, Bioprocess Online
Life Science Leader Editorial Director Dan Schell’s request of me to write about “the” trend in biopharma was a pretty tall order. There’s a lot going on right now. I could go long on the turbulent biopharma economy and its impact on the innovation coming out of emerging biotech companies. I could rehash the broken supply chain and why its prognosis is not promising. I could write about RNA-anything and likely generate clicks. I could dig into the (still) nascent promise (and peril) of cell and gene therapies. But all that stuff is thoroughly covered regularly around here. It’s all important, but I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.